TCGX Acquisition Corp. II (NASDAQ:TCXB) announced the pricing of its $100 million IPO and its shares are expected to begin trading on the Nasdaq under the symbol “TCXB” on Friday, October 16, 2026.
The new SPAC aims to combine with a target company in the life sciences and medical technology sectors.
TCGX Acquisition Corp. II is to be led by Chief Executive Officer Chen Yu, MD, MBA and Chief Financial Officer Craig Skaling. Joshua Cohen, Mark McKenna and Michael Henderson will serve on its Board of Directors.
Total SPAC deal count for 2026 year-to-date is now 156. This offering is expected to close on Monday, October 19, 2026.
Guggenheim Securities is acting as the sole book-running manager for the offering. Cooley LLP is serving as Issuer’s Counsel with Davis Polk & Wardwell LLP is serving as Underwriter’s Counsel. WithumSmith+Brown, PC serves as auditor. Odyssey Transfer and Trust Company is acting as trustee.
